Genetic Technologies (GTG.AX) Stock Price

Genetic Technologies Price

ASX·CLOSED
0.04AUD+0.00 (+0.00 %)
Market closed

Revenue at Genetic Technologies has contracted by 1.8% per year over the past 19 years to 7.66 M AUD. For Genetic Technologies, the net margin of -156.8% is up versus -63,583.8% a few years ago.

Genetic Technologies stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Genetic Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genetic Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genetic Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Genetic Technologies Stock Price History
DateGenetic Technologies Price
7/21/20260.04 AUD
7/20/20260.04 AUD
7/17/20260.04 AUD
7/16/20260.04 AUD
7/15/20260.04 AUD
7/14/20260.04 AUD
7/13/20260.04 AUD
7/10/20260.04 AUD
7/9/20260.04 AUD
7/8/20260.04 AUD
7/7/20260.04 AUD
7/6/20260.04 AUD
7/3/20260.04 AUD
7/2/20260.04 AUD
7/1/20260.04 AUD
6/30/20260.04 AUD
6/29/20260.04 AUD
6/26/20260.04 AUD
6/25/20260.04 AUD
6/24/20260.04 AUD
6/23/20260.04 AUD
6/22/20260.04 AUD
6/19/20260.04 AUD
6/18/20260.04 AUD
6/17/20260.04 AUD
6/16/20260.04 AUD
6/15/20260.04 AUD
6/12/20260.04 AUD
6/11/20260.04 AUD
6/10/20260.04 AUD
6/9/20260.04 AUD
6/5/20260.04 AUD
6/4/20260.04 AUD
6/3/20260.04 AUD
6/2/20260.04 AUD
6/1/20260.04 AUD
5/29/20260.04 AUD
5/28/20260.04 AUD
5/27/20260.04 AUD
5/26/20260.04 AUD
5/25/20260.04 AUD
5/22/20260.04 AUD
5/21/20260.04 AUD
5/20/20260.04 AUD
5/19/20260.04 AUD
5/18/20260.04 AUD
5/15/20260.04 AUD
5/14/20260.04 AUD
5/13/20260.04 AUD
5/12/20260.04 AUD
5/11/20260.04 AUD
5/8/20260.04 AUD
5/7/20260.04 AUD
5/6/20260.04 AUD
5/5/20260.04 AUD
5/4/20260.04 AUD
5/1/20260.04 AUD
4/30/20260.04 AUD
4/29/20260.04 AUD
4/28/20260.04 AUD
4/27/20260.04 AUD
4/24/20260.04 AUD
4/23/20260.04 AUD
4/22/20260.04 AUD
4/21/20260.04 AUD
4/20/20260.04 AUD
4/17/20260.04 AUD
4/16/20260.04 AUD
4/15/20260.04 AUD
4/14/20260.04 AUD
4/13/20260.04 AUD
4/10/20260.04 AUD
4/9/20260.04 AUD
4/8/20260.04 AUD
4/7/20260.04 AUD
4/2/20260.04 AUD
4/1/20260.04 AUD
3/31/20260.04 AUD
3/30/20260.04 AUD
3/27/20260.04 AUD
3/26/20260.04 AUD
3/25/20260.04 AUD
3/24/20260.04 AUD
3/23/20260.04 AUD
3/20/20260.04 AUD
3/19/20260.04 AUD
3/18/20260.04 AUD
3/17/20260.04 AUD
3/16/20260.04 AUD
3/13/20260.04 AUD
3/12/20260.04 AUD
3/11/20260.04 AUD
3/10/20260.04 AUD
3/9/20260.04 AUD
3/6/20260.04 AUD
3/5/20260.04 AUD
3/4/20260.04 AUD
3/3/20260.04 AUD
3/2/20260.04 AUD
2/27/20260.04 AUD
2/26/20260.04 AUD
2/25/20260.04 AUD
2/24/20260.04 AUD
2/23/20260.04 AUD
2/20/20260.04 AUD
2/19/20260.04 AUD
2/18/20260.04 AUD
2/17/20260.04 AUD
2/16/20260.04 AUD
2/13/20260.04 AUD
2/12/20260.04 AUD
2/11/20260.04 AUD
2/10/20260.04 AUD
2/9/20260.04 AUD
2/6/20260.04 AUD
2/5/20260.04 AUD
2/4/20260.04 AUD
2/3/20260.04 AUD
2/2/20260.04 AUD
1/30/20260.04 AUD
1/29/20260.04 AUD
1/28/20260.04 AUD
1/27/20260.04 AUD
1/23/20260.04 AUD
1/22/20260.04 AUD
1/21/20260.04 AUD
1/20/20260.04 AUD
1/19/20260.04 AUD
1/16/20260.04 AUD
1/15/20260.04 AUD
1/14/20260.04 AUD
1/13/20260.04 AUD
1/12/20260.04 AUD
1/9/20260.04 AUD
1/8/20260.04 AUD
1/7/20260.04 AUD
1/6/20260.04 AUD
1/5/20260.04 AUD
1/2/20260.04 AUD
12/31/20250.04 AUD
12/30/20250.04 AUD
12/29/20250.04 AUD
12/24/20250.04 AUD
12/23/20250.04 AUD
12/22/20250.04 AUD
12/19/20250.04 AUD
12/18/20250.04 AUD
12/17/20250.04 AUD
12/16/20250.04 AUD
12/15/20250.04 AUD
12/12/20250.04 AUD
12/11/20250.04 AUD
12/10/20250.04 AUD
12/9/20250.04 AUD
12/8/20250.04 AUD
12/5/20250.04 AUD
12/4/20250.04 AUD
12/3/20250.04 AUD
12/2/20250.04 AUD
12/1/20250.04 AUD
11/28/20250.04 AUD
11/27/20250.04 AUD
11/26/20250.04 AUD
11/25/20250.04 AUD
11/24/20250.04 AUD
11/21/20250.04 AUD
11/20/20250.04 AUD
11/19/20250.04 AUD
11/18/20250.04 AUD
11/17/20250.04 AUD
11/14/20250.04 AUD
11/13/20250.04 AUD
11/12/20250.04 AUD
11/11/20250.04 AUD
11/10/20250.04 AUD
11/7/20250.04 AUD
11/6/20250.04 AUD
11/5/20250.04 AUD
11/4/20250.04 AUD
11/3/20250.04 AUD
10/31/20250.04 AUD
10/30/20250.04 AUD
10/29/20250.04 AUD
10/28/20250.04 AUD
10/27/20250.04 AUD
10/24/20250.04 AUD
10/23/20250.04 AUD
10/22/20250.04 AUD
10/21/20250.04 AUD
10/20/20250.04 AUD
10/17/20250.04 AUD
10/16/20250.04 AUD
10/15/20250.04 AUD
10/14/20250.04 AUD
10/13/20250.04 AUD
10/10/20250.04 AUD
10/9/20250.04 AUD
10/8/20250.04 AUD
10/7/20250.04 AUD
10/6/20250.04 AUD
10/3/20250.04 AUD
10/2/20250.04 AUD
10/1/20250.04 AUD
9/30/20250.04 AUD
9/29/20250.04 AUD
9/26/20250.04 AUD
9/25/20250.04 AUD
9/24/20250.04 AUD
9/23/20250.04 AUD
9/22/20250.04 AUD
9/19/20250.04 AUD
9/18/20250.04 AUD
9/17/20250.04 AUD
9/16/20250.04 AUD
9/15/20250.04 AUD
9/12/20250.04 AUD
9/11/20250.04 AUD
9/10/20250.04 AUD
9/9/20250.04 AUD
9/8/20250.04 AUD
9/5/20250.04 AUD
9/4/20250.04 AUD
9/3/20250.04 AUD
9/2/20250.04 AUD
9/1/20250.04 AUD
8/29/20250.04 AUD
8/28/20250.04 AUD
8/27/20250.04 AUD
8/26/20250.04 AUD
8/25/20250.04 AUD
8/22/20250.04 AUD
8/21/20250.04 AUD
8/20/20250.04 AUD
8/19/20250.04 AUD
8/18/20250.04 AUD
8/15/20250.04 AUD
8/14/20250.04 AUD
8/13/20250.04 AUD
8/12/20250.04 AUD
8/11/20250.04 AUD
8/8/20250.04 AUD
8/7/20250.04 AUD
8/6/20250.04 AUD
8/5/20250.04 AUD
8/4/20250.04 AUD
8/1/20250.04 AUD
7/31/20250.04 AUD
7/30/20250.04 AUD
7/29/20250.04 AUD
7/28/20250.04 AUD
7/25/20250.04 AUD
7/24/20250.04 AUD
Access this data via the Eulerpool API
Get Free API Key

Genetic Technologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
518,500.00 AUD
-7.74 M AUD
-8.40 M AUD
Jan 1, 2018
189,300.00 AUD
-6.11 M AUD
-5.46 M AUD
Jan 1, 2019
25,400.00 AUD
-6.00 M AUD
-6.43 M AUD
Jan 1, 2020
9,900.00 AUD
-6.54 M AUD
-6.29 M AUD
Jan 1, 2021
120,600.00 AUD
-7.69 M AUD
-7.08 M AUD
Jan 1, 2022
6.79 M AUD
-7.57 M AUD
-7.13 M AUD
Jan 1, 2023
8.69 M AUD
-10.19 M AUD
-11.75 M AUD
Jan 1, 2024
7.66 M AUD
-10.61 M AUD
-12.02 M AUD

Genetic Technologies Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 23, 2026, 3:44 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESB
2009201020112012201320142015201620172018201920202021202220232024
12.009.004.003.003.004.002.00––––––6.008.007.00
-20.00-25.00-55.56-25.00–33.33-50.00–––––––33.33-12.50
75.0077.7850.0033.3333.3350.0050.00––––––50.0050.0042.86
9.007.002.001.001.002.001.003.003.003.003.003.003.003.004.003.00
-7.00-7.001.00-11.00-9.00-9.00-9.00-8.00-7.00-6.00-5.00-6.00-7.00-7.00-10.00-10.00
-58.33-77.7825.00-366.67-300.00-225.00-450.00––––––-116.67-125.00-142.86
-7.00-9.00–-5.00-9.00-10.00-8.00-8.00-8.00-5.00-6.00-6.00-7.00-7.00-11.00-12.00
40.0028.57––80.0011.11-20.00––-37.5020.00–16.67–57.149.09
0.400.410.430.490.510.621.151.842.272.612.824.160.090.100.110.14
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Genetic Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genetic Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genetic Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Genetic Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genetic Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Genetic Technologies stock margins

The Genetic Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genetic Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genetic Technologies.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
5.03 %
-1,493.19 %
-1,620.79 %
Jan 1, 2018
-58.53 %
-3,225.41 %
-2,886.37 %
Jan 1, 2019
-987.40 %
-23,614.57 %
-25,297.64 %
Jan 1, 2020
-925.25 %
-66,014.14 %
-63,583.84 %
Jan 1, 2021
-41.38 %
-6,372.89 %
-5,868.66 %
Jan 1, 2022
55.65 %
-111.41 %
-104.95 %
Jan 1, 2023
50.09 %
-117.37 %
-135.28 %
Jan 1, 2024
50.94 %
-138.49 %
-156.78 %

Genetic Technologies Stock Revenue, EBIT, Earnings per Share

The Genetic Technologies earnings per share therefore indicates how much revenue Genetic Technologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2018
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2019
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2020
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2021
0.00 AUD
-0.09 AUD
-0.08 AUD
Jan 1, 2022
0.07 AUD
-0.08 AUD
-0.07 AUD
Jan 1, 2023
0.08 AUD
-0.10 AUD
-0.11 AUD
Jan 1, 2024
0.06 AUD
-0.08 AUD
-0.09 AUD

Genetic Technologies business model & stock analysis

Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years.

Genetic Technologies SWOT Analysis

Strengths

Genetic Technologies Ltd has a strong portfolio of intellectual property rights and patents in the field of genetic testing and analysis. The company's proprietary technologies and algorithms provide a competitive advantage.

The company has established strong partnerships and collaborations with leading research institutions and pharmaceutical companies, enhancing its reputation and access to valuable resources and expertise.

Genetic Technologies Ltd has a diverse and experienced team of scientists, researchers, and professionals who contribute to the company's innovation and success in developing advanced genetic tests and solutions.

Weaknesses

The company heavily relies on a limited number of key partnerships for the commercialization of its products and services. Any disruption or termination of these partnerships could adversely affect Genetic Technologies Ltd's revenue and growth prospects.

Genetic Technologies Ltd faces significant competition from both established players and emerging companies in the genetic testing industry. This intense competition may impact the company's market share and pricing power.

The company's financial performance has been inconsistent, with periods of losses and negative cash flows. This may limit its ability to invest in research and development and hinder the company's growth potential.

Opportunities

The growing demand for personalized medicine and advancements in genomic research present significant opportunities for Genetic Technologies Ltd. The company can leverage its expertise and technology to develop new genetic tests and personalized treatment solutions.

Expansion into new geographic markets, particularly emerging economies, can be an attractive opportunity for Genetic Technologies Ltd to tap into untapped customer bases and increase its market reach.

Strategic partnerships with healthcare providers and payers can help Genetic Technologies Ltd in expanding access to its genetic tests and services, while also ensuring reimbursement and insurance coverage for patients.

Threats

Changing regulations and legal challenges related to genetic testing and data privacy can pose significant threats to Genetic Technologies Ltd's operations. Compliance with evolving regulatory frameworks requires continuous investment and attention.

Rapid technological advancements and new entrants in the genetic testing industry can lead to disruptions and make it crucial for Genetic Technologies Ltd to stay at the forefront of innovation to maintain its competitive position.

Economic downturns and uncertainties can impact consumer spending on discretionary services, which may include genetic testing. Genetic Technologies Ltd needs to be prepared to navigate potential market fluctuations and maintain its customer base.

Genetic Technologies Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Genetic Technologies historical P/E ratio, EBIT multiple, and P/S ratio

Genetic Technologies annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Genetic Technologies shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
2.27 B Stocks
Jan 1, 2018
2.61 B Stocks
Jan 1, 2019
2.82 B Stocks
Jan 1, 2020
4.16 B Stocks
Jan 1, 2021
89.41 M Stocks
Jan 1, 2022
96.49 M Stocks
Jan 1, 2023
106.09 M Stocks
Jan 1, 2024
138.36 M Stocks

Genetic Technologies stock splits

In Genetic Technologies's history, there have been no stock splits.
Price targets and forecasts for Genetic Technologies are not yet available.

Genetic Technologies Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
9/2/2014-0.28AUD2.54 MAUD2014 Q4

Genetic Technologies shareholder structure

% Name
840.92830%
Walker (Michael)
Walker (Michael)
19.14814%
Nicols (Steven)
Nicols (Steven)
1.76351%
Wright (Warwick)
Wright (Warwick)
1.71547%
Rubenstein (Peter Irwin)
Rubenstein (Peter Irwin)
1.55598%
Muchnicki (Jerzy)
Muchnicki (Jerzy)
1.04475%
Doma 193 Pty. Ltd.
Doma 193 Pty. Ltd.

Genetic Technologies Executives and Management Board

SM

Mr. Simon Morriss

Chief Executive Officer

Compensation628,670.00 AUD
KC

Mr. Kevin Camilleri

Chief Executive Officer - EasyDNA

Compensation254,584.00 AUD
CS

Mr. Carl Stubbings

Chief Commercial Officer

Compensation250,593.00 AUD
RA

Dr. Richard Allman

(57)

Chief Scientific Officer

Compensation224,645.00 AUD
PR

Mr. Peter Rubinstein

Non-Executive Independent Chairman of the Board

Compensation169,593.00 AUD

Genetic Technologies Supply Chain

Frequently asked questions about Genetic Technologies

The business model of Genetic Technologies Ltd revolves around genetic analysis and testing services. The company specializes in developing and commercializing genetic risk assessment tools for various diseases and conditions. Genetic Technologies uses advanced genetic screening and analysis techniques to assess an individual's predisposition or susceptibility to certain diseases, thereby aiding in personalized healthcare and preventive medicine. By leveraging its proprietary technologies and intellectual property, Genetic Technologies aims to provide valuable genetic insights and solutions to healthcare providers, insurance companies, and individuals worldwide.

All fundamentals and in-depth analysis of Genetic Technologies

Our stock analysis for Genetic Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genetic Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Genetic Technologies Stock
Genetic Technologies Revenue→
Genetic Technologies Stock
Genetic Technologies Net Income→
Genetic Technologies Stock
Genetic Technologies P/E→
Genetic Technologies Stock
Genetic Technologies P/S→
Genetic Technologies Stock
Genetic Technologies EBIT→
Genetic Technologies Stock
Genetic Technologies Dividend→
Genetic Technologies Stock
Genetic Technologies Directors Dealings→
Genetic Technologies Stock
Genetic Technologies Stocks→
Genetic Technologies Stock
Genetic Technologies Market capitalization→
Genetic Technologies Stock
Genetic Technologies Debt→
Genetic Technologies Stock
Genetic Technologies Liabilities→
Genetic Technologies Stock
Genetic Technologies Equity→
Genetic Technologies Stock
Genetic Technologies AAQS→
Genetic Technologies Stock
Genetic Technologies Employees→
Genetic Technologies Stock
Genetic Technologies ROE→
Genetic Technologies Stock
Genetic Technologies ROA→
Genetic Technologies Stock
Genetic Technologies ROCE→
Genetic Technologies Stock
Genetic Technologies News→
Genetic Technologies Stock
Genetic Technologies Analyst Price Targets→

Health Stocks

Genetics Generation AdvancementGenetic SignaturesGenex PharmaceuticalGeneSystem CoGenexineGenesis IBRC IndiaGenfitGenesis Fertility Center PCLGeninusGenertec Universal Medical Group CoGenmab ASGeneReach BiotechnologyAll Stocks A–Z →